• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Teva Pharmaceutical Industries ADR (NY: TEVA )

    17.20 +0.70 (+4.24%)
    Streaming Delayed Price Updated: 1:58 PM EDT, Jul 25, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 5,806,921
    Open 16.50
    Bid (Size) 17.19 (42)
    Ask (Size) 17.20 (25)
    Prev. Close 16.50
    Today's Range 16.50 - 17.33
    52wk Range 8.055 - 17.69
    Shares Outstanding 1,110,352,397
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Teva and Sanofi Announce Accelerated Timeline for Anti-TL1A Phase 2b Program in Patients with Inflammatory Bowel Disease
    From Teva Pharmaceutical Industries Limited
    Via Business Wire
    Why Hims & Hers Heath Shares Are Surging Today
    Hims & Hers Health Inc. (NYSE: HIMS) shares are moving higher on Monday amidst the announcement of Kåre Schultz's appointment to the Board of Directors. 
    Via Benzinga

    Performance

    YTD
    +61.20%
    +61.20%
    1 Month
    +4.31%
    +4.31%
    3 Month
    +32.21%
    +32.21%
    6 Month
    +43.69%
    +43.69%
    1 Year
    +104.76%
    +104.76%

    More News

    Read More
    $100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today
    Via Benzinga
    Teva's Migraine Treatment Found Effective For Children As Young As 6
    Via Benzinga
    Teva Announces First Phase 3 Evidence of Efficacy and Safety of an Anti-CGRP Monoclonal Antibody in Children in AJOVY® (fremanezumab) SPACE Trial for Prevention of Episodic Migraine
    From Teva Pharmaceutical Industries Limited
    Via Business Wire
    Breaking Down Teva Pharmaceutical Indus: 5 Analysts Share Their Views
    Via Benzinga
    If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,100 Today
    Via Benzinga
    Jim Cramer Says Don't Sell Match Group: 'You've Just Got A Very, Very Smart Investor In There'
    Via Benzinga
    3 No-Brainer Stocks to Buy With $200 Right Now
    Via The Motley Fool
    Here's How Much $1000 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth Today
    Via Benzinga
    Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem
    Via MarketBeat
    Teva to Host Conference Call to Discuss Second Quarter 2024 Financial Results at 8 a.m. ET on July 31, 2024
    From Teva Pharmaceutical Industries Limited
    Via Business Wire
    FTC Crackdown on Teva Pharmaceuticals Over Inhaler Patent Abuse
    Via Benzinga
    Topics Intellectual Property
    Exposures Intellectual Property
    Dr. Reddy's Labs Stock Sees Improved Technical Strength
    Via Investor's Business Daily
    New AJOVY® (fremanezumab) Migraine Prevention Data Challenges Treatment Pauses
    From Teva Pharmaceutical Industries Limited
    Via Business Wire
    Teva Reaches Agreement With the Israel Tax Authority to Resolve All Pending Litigation for the Company's Taxable Years 2008-2020
    From Teva Pharmaceutical Industries Limited
    Via Business Wire
    Teva Announces Launch of Authorized Generic of Victoza® (liraglutide injection 1.8mg), in the United States
    From Teva Pharmaceutical Industries Limited
    Via Business Wire
    Teva Engages In Settlement Talks Over Medicare Kickback Allegations
    Via Benzinga
    Topics Lawsuit
    Exposures Financial Legal
    Concerpt Therapeutics Shares Are Trading Lower: What You Need To Know
    Via Benzinga
    Topics Lawsuit
    Exposures Financial Legal
    7 A-Rated Biotech Stocks Worth Betting on in June
    Via InvestorPlace
    What is a Bull Flag Pattern? Explanation and Examples
    Via MarketBeat
    Teva to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
    From Teva Pharmaceutical Industries Limited
    Via Business Wire
    New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate)
    From Teva Pharmaceutical Industries Limited
    Via Business Wire
    Teva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024
    From Teva Pharmaceutical Industries Limited
    Via Business Wire
    2 Generic Drug Makers With Growing Runways
    Via MarketBeat
    Topics Intellectual Property
    Exposures Intellectual Property
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.